AstraZeneca continued to see strong earnings boosted primarily by its oncology branch, as well as its respiratory and immunology segment.
Trending
- Does this chemical really make you fall in love?
- Arundhati Roy boycotts Berlin fest premiere of her revamped 1980s cult classic – the film shows why
- ‘It was pretty gnarly’: Sinners cinematographer on bugs, blood splatters and Hollywood ‘boys’ club’ | Ents & Arts News
- Second US carrier heads to Middle East
- Why German building projects run over time and budget
- High Court dismisses challenge to single-sex toilet guidance
- How Bangladesh Went From Revolution to Elections
- BrewDog owners call time on craft beer pioneer | Money News
